ANI Pharmaceuticals (NASDAQ:ANIP) Stock: Insider Meredith Cook Sells 500 Shares

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 500 shares of the business’s stock in a transaction on Tuesday, October 13th. The shares were sold at an average price of $73.59, for a total value of $36,795.00. Following the completion of the sale, the vice president directly owned 73,424 shares in the company, valued at approximately $5,403,272.16. This represents a 0.68% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Meredith Cook also recently made the following trade(s):

• On Monday, September 14th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $70.79, for a total value of $35,395.00.
• On Thursday, August 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $75.48, for a total value of $37,740.00.

ANI Pharmaceuticals Price Performance

ANI Pharmaceuticals stock traded down $2.75 during mid-day trading on Tuesday, hitting $70.84. 331,803 shares of the company were exchanged, compared to its average volume of 444,460. The company has a market capitalization of $1.63 billion, a PE ratio of 15.27, a price-to-earnings-growth ratio of 2.37 and a beta of 0.50. The business has a fifty day moving average of $74.11 and a 200 day moving average of $78.04. ANI Pharmaceuticals, Inc. has a 1-year low of $69.58 and a 1-year high of $97.00. The company has a quick ratio of 2.41, a current ratio of 2.91 and a debt-to-equity ratio of 0.99.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, beating the consensus estimate of $2.04 by $0.17. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The company had revenue of $266.04 million for the quarter, compared to the consensus estimate of $260.13 million. During the same quarter in the previous year, the company earned $1.80 EPS. The firm’s revenue for the quarter was up 25.8% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, sell-side analysts expect that ANI Pharmaceuticals, Inc. will post 7.76 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ANIP. Arrowstreet Capital Limited Partnership increased its position in ANI Pharmaceuticals by 19.3% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 564,360 shares of the specialty pharmaceutical company’s stock valued at $43,399,000 after acquiring an additional 91,153 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of ANI Pharmaceuticals by 8.9% during the first quarter. Dimensional Fund Advisors LP now owns 531,190 shares of the specialty pharmaceutical company’s stock worth $40,843,000 after purchasing an additional 43,523 shares in the last quarter. Ranger Investment Management L.P. acquired a new position in shares of ANI Pharmaceuticals during the second quarter worth approximately $28,406,000. Deutsche Bank AG acquired a new position in shares of ANI Pharmaceuticals during the second quarter worth approximately $26,775,000. Finally, William Blair Investment Management LLC bought a new stake in shares of ANI Pharmaceuticals during the second quarter valued at approximately $21,372,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Guggenheim reduced their price target on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a research report on Monday, August 10th. Wall Street Zen lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Leerink Partners began coverage on shares of ANI Pharmaceuticals in a report on Wednesday, September 9th. They set an “outperform” rating and a $104.00 price objective for the company. Weiss Ratings cut shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, August 11th. Finally, Oppenheimer initiated coverage on ANI Pharmaceuticals in a report on Wednesday, September 23rd. They issued a “market perform” rating and a $85.00 target price on the stock. Three research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $99.60.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and commercializes branded and generic prescription medicines. The company focuses on products with complex formulations, difficult-to-manufacture dosage forms and limited competition, serving therapeutic areas that include rare diseases, ophthalmology, endocrinology, central nervous system conditions and other specialty markets.

ANI’s portfolio includes Cortrophin Gel (repository corticotropin injection), a specialty therapy used for certain inflammatory and autoimmune conditions, as well as a range of established brand and generic products.